Middle East and Africa Wegovy Market Size, Share & Trends Analysis Report By Drug Type (Branded Semaglutide, Wegovy , Generic/Biosimilar Semaglutide, Pipeline biosimilars  ), By Route of Administration (Subcutaneous Injection, Oral Formulations), By Country (Brazil, Mexico, Argentina, Chile, Colombia) and Forecast, 2026-2034

Middle East and Africa Wegovy Market Trends

Oral GLP-1 formulations broaden the treatment model

The obesity-therapy landscape is moving beyond once-weekly injections toward oral GLP-1 delivery. Wegovy tablets reached more than 3 million prescriptions within approximately five months of their January 2026 U.S. launch, while 82% of new-to-brand starts were reported among patients new to GLP-1 therapy. Oral semaglutide 25 mg demonstrated approximately 17% mean weight loss versus about 3% for placebo, illustrating how oral delivery could reduce administration barriers.

Technology development is simultaneously raising injectable efficacy. Semaglutide 7.2 mg produced 20.7% mean weight loss at 72 weeks among treatment-adherent participants compared with 17.5% for 2.4 mg and 2.4% for placebo in STEP UP. Novo Nordisk reported that its obesity portfolio reached 3.6 million people worldwide during 2025 while obesity-care sales increased 31% at constant exchange rates, indicating substantial volume expansion alongside dosage innovation.

Middle East and Africa Wegovy Market Drivers

Expanding GLP-1 adoption accelerates obesity pharmacotherapy

Rising clinical acceptance of GLP-1 therapies is strengthening prescription volumes. Novo Nordisk reported approximately 55% volume leadership in weekly injectable GLP-1 therapies in early 2026, while Wegovy had launched in more than 55 countries. International Operations obesity-care performance was supported by regional increases reaching 87%, 63% and 18% across selected operating areas, while adjusted obesity-care sales increased 22% at constant exchange rates in Q1 2026. These indicators reinforce the commercial momentum behind broader obesity-treatment adoption.

Middle East and Africa Wegovy Market Restraints

Pricing, reimbursement and treatment persistence constrain access

Affordability remains a significant barrier because obesity pharmacotherapy can require long-duration treatment and recurring prescriptions. Novo Nordisk's U.S. access initiatives include commercial-insurance programs with patient costs as low as USD 25 per month and a Medicare GLP-1 bridge carrying a USD 50 monthly copay, demonstrating the scale of affordability intervention required even in high-income systems. Oral semaglutide trials also reported adverse-event discontinuation of 6.9% versus 5.9% for placebo, emphasizing persistence considerations alongside pricing constraints.

Middle East and Africa Wegovy Market Opportunities

Oral delivery and higher-dose therapy expand addressable patient pools

The combination of oral semaglutide and higher-dose injections creates opportunities to match therapy with patient preferences and clinical requirements. In a 2026 preference study, 84% of respondents favored a treatment profile resembling oral semaglutide 25 mg over the comparator profile. Meanwhile, 7.2 mg injectable semaglutide achieved 20.7% mean weight reduction, with roughly one-third of participants achieving at least 25% weight loss, supporting differentiated positioning for patients requiring greater efficacy.

Challenges in Middle East and Africa Wegovy Market

Competition and supply scalability intensify commercial pressure

Competitive intensity is increasing as alternative incretin therapies advance. In the 809-participant REDEFINE 4 study, CagriSema delivered 23.0% weight reduction under the treatment-adherent estimand compared with 25.5% for tirzepatide after 84 weeks, while treatment-regimen results were 20.2% and 23.6%, respectively. At the same time, scaling manufacturing, maintaining cold-chain capabilities for injectable products and accommodating oral products create operational complexity as GLP-1 volumes expand across more than 55 Wegovy launch countries.

Middle East and Africa Wegovy Market Segmentation

Segmentation spans drug type, route, dosage strength, patient demographics, BMI, distribution channel, indication, end user, and pricing tier. Among categories for which mandatory numerical data were supplied, Branded Semaglutide dominates with approximately 41.2% of the 2026 drug-type total, followed by Wegovy at 29.1%, Generic/Biosimilar Semaglutide at 17.1% and pipeline biosimilars at 12.6%.

By Drug Type

Branded Semaglutide is the largest supplied subsegment, increasing from USD 118.71 million in 2025 to USD 151.11 million in 2026 and USD 1,041.44 million by 2034 at a 27.29% CAGR. Wegovy advances from USD 106.63 million in 2026 to USD 683.91 million by 2034 at 26.15%.

Generic/biosimilar semaglutide records the fastest CAGR at 28.59%, reaching USD 467.97 million in 2034 from USD 62.60 million in 2026. Pipeline biosimilars increase from USD 46.01 million to USD 307.64 million at 26.81%.

By Route of Administration

Subcutaneous injection remains the established administration format across 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg weekly dosage stages. Oral formulations constitute the emerging alternative. No route-specific revenue or CAGR values were supplied; therefore, numerical market values are not imputed.

The route structure increasingly accommodates both chronic injectable treatment and daily oral administration. The supplied drug-type market totals USD 366.35 million in 2026 and USD 2,500.96 million in 2034, but these totals cannot be mathematically allocated between injection and oral formats without unsupported assumptions.

By Dosage Strength

Dosage segmentation includes 0.25 mg/week, 0.5 mg/week, 1 mg/week, 1.7 mg/week, and 2.4 mg/week. These strengths support dose escalation and maintenance protocols, although the supplied tables provide no individual dosage revenue or CAGR.

Consequently, the USD 366.35 million 2026 drug-type total and USD 2,500.96 million 2034 total are retained only as aggregate reference values rather than apportioned across the five dosage categories.

By Patient Demographics

Adults, elderly patients, and adolescents form the demographic segmentation. Adults represent the core indicated population, while adolescent eligibility extends obesity pharmacotherapy into younger populations; however, no demographic-specific revenue or CAGR values were supplied.

Across the underlying drug-type dataset, aggregate revenue increases more than sixfold from USD 366.35 million in 2026 to USD 2,500.96 million in 2034 at 27.21%, without sufficient data for defensible allocation among the 3 demographic groups.

By BMI Category

The market separates BMI 27–29.9 patients from patients with BMI ≥30. Clinical eligibility commonly differentiates overweight patients with qualifying comorbidities from obesity populations, making BMI central to treatment targeting.

No BMI-specific revenue or CAGR was supplied. Accordingly, neither the USD 366.35 million 2026 drug-type total nor the USD 2,500.96 million 2034 total is assigned between the 2 BMI categories.

By Distribution Channel

Retail pharmacies, hospital pharmacies, online pharmacies, and specialty clinics comprise the principal distribution channels. Pharmacy availability and specialist prescribing infrastructure are particularly important for chronic GLP-1 treatment.

No channel-specific financial values were provided. The 4 channels therefore remain qualitative segmentation categories rather than receiving fabricated allocations from the supplied USD 366.35 million 2026 aggregate.

By Application/Indication

Obesity management is the principal indication, complemented by type 2 diabetes with obesity, cardiovascular risk reduction, and metabolic syndrome. These 4 application categories broaden the clinical framework beyond weight reduction alone.

The supplied dataset contains no indication-level revenue or CAGR. Consequently, the USD 2,500.96 million 2034 drug-type forecast is not apportioned across indications.

By End User

Hospitals, ambulatory surgical centers, weight management clinics, and home care settings constitute the end-user framework. Home-based administration supports chronic therapy, while hospitals and specialist clinics facilitate initiation and monitoring.

No end-user revenue or CAGR figures were supplied. The 4 end-user categories therefore cannot be assigned numerical contributions from the USD 366.35 million 2026 drug-type total.

By Pricing Tier

High-Income Market, Middle-Income Market and Low-Income Market tiers reflect differences in insurance coverage, private spending and pharmaceutical affordability. These 3 tiers influence access and treatment persistence.

No pricing-tier CAGR or revenue values were supplied, preventing defensible allocation of the USD 2,500.96 million 2034 drug-type forecast among income categories.

Middle East and Africa Wegovy Market Counties Outlook

The supplied regional instruction lists Brazil, Mexico, Argentina, Chile and Colombia; these countries are outside the Middle East and Africa geography and have no numerical values in the mandatory dataset. To avoid fabricating regional data, the outlook below uses the six countries actually supplied.

United Arab Emirates

The UAE leads with USD 179.61 million in 2026, approximately 48.9% of the country total, rising to USD 1,242.60 million by 2034 at 27.35% CAGR. It contributes nearly half of the supplied 2026 regional revenue.

Saudi Arabia

Saudi Arabia accounts for approximately 20.2% of 2026 revenue at USD 74.04 million. It reaches USD 548.69 million by 2034 and records the highest supplied country CAGR of 28.45%.

South Africa

South Africa contributes approximately 11.5% at USD 42.13 million in 2026, up from USD 33.08 million in 2025. Revenue is forecast at USD 291.44 million by 2034, representing 27.35% CAGR.

Egypt

Egypt represents approximately 9.4% of the supplied 2026 country total with USD 34.65 million. The country advances to USD 246.12 million in 2034 at a 27.77% CAGR.

Turkey

Turkey generates USD 18.70 million in 2026, or approximately 5.1% of the supplied total, and reaches USD 122.51 million by 2034 at 26.49% CAGR.

Nigeria

Nigeria contributes approximately 5.0% at USD 18.27 million in 2026. Revenue rises to USD 114.99 million by 2034, representing a 25.85% CAGR.

Top players in Middle East and Africa Wegovy Market

1. Novo Nordisk A/S
2. Eli Lilly and Company
3. Sanofi
4. AstraZeneca
5. Pfizer Inc.
6. Boehringer Ingelheim
7. Amgen Inc.
8. Roche
9. Zealand Pharma
10. Structure Therapeutics
11. Viking Therapeutics
12. Innovent Biologics

Top two companies

• Novo Nordisk A/S:Novo Nordisk occupies the central competitive position as the developer and marketer of Wegovy. The company reported approximately 55% global weekly injectable GLP-1 volume leadership in early 2026 and had launched Wegovy in more than 55 countries. Its obesity portfolio reached approximately 3.6 million people during 2025 and generated 31% sales growth at constant exchange rates. The addition of oral semaglutide and 7.2 mg Wegovy expands its delivery and efficacy portfolio. A Middle East and Africa company revenue percentage was not supplied and is therefore not fabricated.
• Eli Lilly and Company: Eli Lilly represents a major competitive force through tirzepatide and oral GLP-1 development. Competitive efficacy pressure is illustrated by REDEFINE 4, where tirzepatide produced 25.5% weight reduction compared with 23.0% for CagriSema under the treatment-adherent estimand after 84 weeks. The FDA also approved Lilly's oral orforglipron in April 2026, strengthening competition in non-injectable obesity therapy. No defensible Middle East and Africa company percentage was provided in the mandatory dataset, so a regional company share is not assigned.

Recent Developments in the Middle East and Africa Wegovy Market

• 2026: Novo Nordisk announced that the Wegovy pill exceeded 3 million prescriptions within approximately five months of U.S. launch and confirmed international rollout activity, including the UAE.
• 2026: The European Commission approved once-daily Wegovy 25 mg pill and Wegovy 7.2 mg injection; oral semaglutide demonstrated approximately 17% mean weight loss versus 3% for placebo.
• 2026: The FDA approved Wegovy HD 7.2 mg after a 54-day review; clinical evidence showed 20.7% mean weight loss among treatment-adherent participants.
• 2026: Novo Nordisk reported adjusted obesity-care sales increasing 22% at constant exchange rates during Q1, while International Operations sales increased 6% at constant exchange rates.
• 2025: STEP UP results showed semaglutide 7.2 mg produced 20.7% mean weight reduction after 72 weeks versus 17.5% for 2.4 mg and 2.4% for placebo among treatment-adherent participants.

Research Methodology

The analysis applies 2025 as the base year, 2026 as the current year, 2022–2024 as the historical period and 2026–2034 as the forecast horizon. Mandatory supplied country values of USD 288.18 million for 2025, USD 367.40 million for 2026 and USD 2,566.35 million for 2034 are retained without modification. Drug-type values are independently retained at USD 288.20 million, USD 366.35 million and USD 2,500.96 million, respectively. Calculated percentage contributions use only these supplied totals, while external clinical and corporate information is used solely for qualitative trends, dynamics, competitive positioning and developments. No unsupported segment, country or company revenue allocation has been introduced.